ID   HCC4006
AC   CVCL_1269
SY   HCC-4006; Hamon Cancer Center 4006
DR   BTO; BTO:0004081
DR   CLO; CLO_0003657
DR   EFO; EFO_0003132
DR   AddexBio; C0016012/4917
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; CRL-2871
DR   BioSample; SAMN03471807
DR   BioSample; SAMN03473288
DR   BioSample; SAMN10988526
DR   cancercelllines; CVCL_1269
DR   Cell_Model_Passport; SIDM01596
DR   ChEMBL-Cells; CHEMBL4523544
DR   ChEMBL-Targets; CHEMBL4523575
DR   Cosmic; 903602
DR   Cosmic; 1028938
DR   Cosmic; 1128250
DR   Cosmic; 1146936
DR   Cosmic; 1802302
DR   Cosmic; 2015233
DR   DepMap; ACH-000066
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   GEO; GSM63351
DR   GEO; GSM108873
DR   GEO; GSM108874
DR   GEO; GSM253408
DR   GEO; GSM434286
DR   GEO; GSM794399
DR   GEO; GSM844552
DR   GEO; GSM887055
DR   GEO; GSM888125
DR   IARC_TP53; 30035
DR   IGRhCellID; HCC4006GEO
DR   LiGeA; CCLE_139
DR   PharmacoDB; HCC4006_502_2019
DR   PRIDE; PXD002556
DR   Progenetix; CVCL_1269
DR   PubChem_Cell_line; CVCL_1269
DR   Wikidata; Q54881724
RX   PubMed=16187286;
RX   PubMed=20679594;
RX   PubMed=22460905;
RX   PubMed=22961666;
RX   PubMed=23733853;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26361996;
RX   PubMed=26589293;
RX   PubMed=29681454;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31395879;
WW   http://www.utsouthwestern.edu/edumedia/edufiles/about_us/admin_offices/technology_development/available_technologies/cell-lines.pdf
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: EGFR genetic alteration cell panel (ATCC TCP-1027).
CC   Part of: TCGA-110-CL cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 46.8 hours (PubMed=29681454); ~41 hours (ATCC=CRL-2871).
CC   HLA typing: A*33:03,33:03; B*44:03,44:03; C*07:01,07:01; DQB1*02:02,02:02; DRB1*07:01,14:05 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu747_Glu749del (c.2239_2247delTAAGAGAA); ClinVar=VCV000177765; Zygosity=Heterozygous (ATCC=CRL-2871; DepMap=ACH-000066).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205His (c.613T>C); ClinVar=VCV000376685; Zygosity=Homozygous (DepMap=ACH-000066).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.52%; Native American=0%; East Asian, North=5.13%; East Asian, South=0%; South Asian=0%; European, North=54.8%; European, South=38.54% (PubMed=30894373).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): AddexBio=C0016012/4917; ATCC=CRL-2871; PubMed=20679594; PubMed=25877200
ST   Amelogenin: X (AddexBio=C0016012/4917; ATCC=CRL-2871; PubMed=25877200)
ST   Amelogenin: X,Y (PubMed=20679594)
ST   CSF1PO: 10
ST   D13S317: 11,12
ST   D16S539: 11,12 (AddexBio=C0016012/4917; ATCC=CRL-2871; PubMed=20679594)
ST   D16S539: 12 (PubMed=25877200)
ST   D19S433: 12,13
ST   D18S51: 19
ST   D21S11: 31
ST   D2S1338: 17,24
ST   D3S1358: 16,18 (ATCC=CRL-2871)
ST   D3S1358: 18 (PubMed=25877200)
ST   D5S818: 12
ST   D7S820: 9,12
ST   D8S1179: 10,14
ST   FGA: 21,22
ST   Penta D: 9,14
ST   Penta E: 7,13
ST   TH01: 7
ST   TPOX: 8,9
ST   vWA: 16,17
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   >50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 36
//
RX   PubMed=16187286; DOI=10.1002/ijc.21491;
RA   Garnis C., Lockwood W.W., Vucic E., Ge Y., Girard L., Minna J.D.,
RA   Gazdar A.F., Lam S., MacAulay C., Lam W.L.;
RT   "High resolution analysis of non-small cell lung cancer cell lines by
RT   whole genome tiling path array CGH.";
RL   Int. J. Cancer 118:1556-1564(2006).
//
RX   PubMed=20679594; DOI=10.1093/jnci/djq279; PMCID=PMC2935474;
RA   Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.;
RT   "Lung cancer cell lines as tools for biomedical discovery and
RT   research.";
RL   J. Natl. Cancer Inst. 102:1310-1321(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112; PMCID=PMC3567922;
RA   Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P.,
RA   Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F.,
RA   Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J.,
RA   Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L.,
RA   Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D.,
RA   Heymach J.V.;
RT   "Proteomic profiling identifies dysregulated pathways in small cell
RT   lung cancer and novel therapeutic targets including PARP1.";
RL   Cancer Discov. 2:798-811(2012).
//
RX   PubMed=23733853; DOI=10.1101/gr.152322.112; PMCID=PMC3759720;
RA   Jia P.-L., Jin H.-L., Meador C.B., Xia J.-F., Ohashi K., Liu L.,
RA   Pirazzoli V., Dahlman K.B., Politi K., Michor F., Zhao Z.-M., Pao W.;
RT   "Next-generation sequencing of paired tyrosine kinase
RT   inhibitor-sensitive and -resistant EGFR mutant lung cancer cell lines
RT   identifies spectrum of DNA changes associated with drug resistance.";
RL   Genome Res. 23:1434-1445(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26361996; DOI=10.1016/j.jprot.2015.09.003;
RA   Grundner-Culemann K., Dybowski J.N., Klammer M., Tebbe A., Schaab C.,
RA   Daub H.;
RT   "Comparative proteome analysis across non-small cell lung cancer cell
RT   lines.";
RL   J. Proteomics 130:1-10(2016).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=29681454; DOI=10.1016/j.cell.2018.03.028; PMCID=PMC5935540;
RA   McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R.,
RA   Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M.,
RA   Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L.,
RA   Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J.,
RA   DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A.,
RA   Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S.,
RA   Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G.,
RA   Posner B.A., Minna J.D., Kim H.S., White M.A.;
RT   "Chemistry-first approach for nomination of personalized treatment in
RT   lung cancer.";
RL   Cell 173:864-878.e29(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31395879; DOI=10.1038/s41467-019-11415-2; PMCID=PMC6687785;
RA   Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M.,
RA   van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.;
RT   "Comprehensive transcriptomic analysis of cell lines as models of
RT   primary tumors across 22 tumor types.";
RL   Nat. Commun. 10:3574.1-3574.11(2019).
//